Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer
Emmanuel Douez, Émilie Allard-Vannier, Imène Ait Mohamed Amar, Louis Jolivet, Fanny Boursin, Aurélie Maisonial‐Besset, Tiffany Witkowski, Jean‐Michel Chezal, Cyril Colas, Stéphanie Letast, Etienne Auvert, Caroline Denevault‐Sabourin, Nicolas Aubrey, Nicolas Joubert
Topics & Concepts
Antibody-drug conjugateConjugateIn vivoEx vivoPharmacologyLinkerBiodistributionInternalizationMedicineTrastuzumabImmunoconjugateCytotoxicityDrugBreast cancerCancer researchChemistryCancerIn vitroAntibodyMonoclonal antibodyImmunologyInternal medicineReceptorBiochemistryBiologyOperating systemComputer scienceMathematicsBiotechnologyMathematical analysisHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy research